1. Home
  2. JFIN vs KALV Comparison

JFIN vs KALV Comparison

Compare JFIN & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JFIN
  • KALV
  • Stock Information
  • Founded
  • JFIN 2011
  • KALV N/A
  • Country
  • JFIN China
  • KALV United States
  • Employees
  • JFIN N/A
  • KALV N/A
  • Industry
  • JFIN Finance: Consumer Services
  • KALV Biotechnology: Pharmaceutical Preparations
  • Sector
  • JFIN Finance
  • KALV Health Care
  • Exchange
  • JFIN Nasdaq
  • KALV Nasdaq
  • Market Cap
  • JFIN 682.1M
  • KALV 796.4M
  • IPO Year
  • JFIN 2019
  • KALV N/A
  • Fundamental
  • Price
  • JFIN $11.15
  • KALV $10.97
  • Analyst Decision
  • JFIN
  • KALV Strong Buy
  • Analyst Count
  • JFIN 0
  • KALV 8
  • Target Price
  • JFIN N/A
  • KALV $26.43
  • AVG Volume (30 Days)
  • JFIN 90.9K
  • KALV 1.5M
  • Earning Date
  • JFIN 11-19-2025
  • KALV 09-11-2025
  • Dividend Yield
  • JFIN 7.06%
  • KALV N/A
  • EPS Growth
  • JFIN 33.85
  • KALV N/A
  • EPS
  • JFIN 4.21
  • KALV N/A
  • Revenue
  • JFIN $908,895,698.00
  • KALV $1,426,000.00
  • Revenue This Year
  • JFIN N/A
  • KALV N/A
  • Revenue Next Year
  • JFIN N/A
  • KALV $213.43
  • P/E Ratio
  • JFIN $2.68
  • KALV N/A
  • Revenue Growth
  • JFIN 8.19
  • KALV N/A
  • 52 Week Low
  • JFIN $5.18
  • KALV $7.30
  • 52 Week High
  • JFIN $19.23
  • KALV $17.28
  • Technical
  • Relative Strength Index (RSI)
  • JFIN 44.45
  • KALV 32.68
  • Support Level
  • JFIN $10.18
  • KALV $11.93
  • Resistance Level
  • JFIN $11.64
  • KALV $12.04
  • Average True Range (ATR)
  • JFIN 0.46
  • KALV 0.56
  • MACD
  • JFIN 0.17
  • KALV -0.21
  • Stochastic Oscillator
  • JFIN 73.97
  • KALV 10.10

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: